% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Mittelstadt:274472,
      author       = {S. Mittelstadt and O. Kelemen and J. Admard and A. Gschwind
                      and A. Koch and S. Wörz and E. Oberlechner and T. Engler
                      and I. Bonzheim and A. Staebler and N. Weidner and F.
                      Stubenrauch and T. Iftner and O. Riess and C. Schroeder$^*$
                      and S. Kommoss and S. Ossowski$^*$},
      title        = {{D}etection of circulating cell-free {HPV} {DNA} of 13
                      {HPV} types for patients with cervical cancer as potential
                      biomarker to monitor therapy response and to detect
                      relapse.},
      journal      = {British journal of cancer},
      volume       = {128},
      number       = {11},
      issn         = {0007-0920},
      address      = {Edinburgh},
      publisher    = {Nature Publ. Group},
      reportid     = {DKFZ-2023-00617},
      pages        = {2097-2103},
      year         = {2023},
      note         = {2023 Jun;128(11):2097-2103},
      abstract     = {HPV-related cervical cancer (CC) is the fourth most
                      frequent cancer in women worldwide. Cell-free tumour DNA is
                      a potent biomarker to detect treatment response, residual
                      disease, and relapse. We investigated the potential use of
                      cell-free circulating HPV-DNA (cfHPV-DNA) in plasma of
                      patients with CC.cfHPV-DNA levels were measured using a
                      highly sensitive next-generation sequencing-based approach
                      targeting a panel of 13 high-risk HPV types.Sequencing was
                      performed in 69 blood samples collected from 35 patients, of
                      which 26 were treatment-naive when the first liquid biopsy
                      sample was retrieved. cfHPV-DNA was successfully detected in
                      22/26 $(85\%)$ cases. A significant correlation between
                      tumour burden and cfHPV-DNA levels was observed: cfHPV-DNA
                      was detectable in all treatment-naive patients with
                      advanced-stage disease (17/17, FIGO IB3-IVB) and in 5/9
                      patients with early-stage disease (FIGO IA-IB2). Sequential
                      samples revealed a decrease of cfHPV-DNA levels in 7
                      patients corresponding treatment response and an increase in
                      a patient with relapse.In this proof-of-concept study we
                      demonstrated the potential of cfHPV-DNA as a biomarker for
                      therapy monitoring in patients with primary and recurrent
                      CC. Our findings facilitate the development of a sensitive
                      and precise, non-invasive, inexpensive, and easily
                      accessible tool in CC diagnosis, therapy monitoring and
                      follow-up.},
      cin          = {TU01},
      ddc          = {610},
      cid          = {I:(DE-He78)TU01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:36973448},
      doi          = {10.1038/s41416-023-02233-x},
      url          = {https://inrepo02.dkfz.de/record/274472},
}